Dyne Therapeutics Inc
NASDAQ:DYN
Intrinsic Value
Dyne Therapeutics, Inc. engages in developing innovative life-transforming therapies for genetically driven muscle diseases. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of DYN.
Dyne Therapeutics Inc's market capitalization is 2B USD.
DYN stock price is 24.73 USD.
DYN.
DYN. Open DCF Valuation
DYN. Open Relative Valuation
DYN has upside potential of 56% compared to the average analyst price target.
Open Wall St Estimates
DYN has negative Free Cash Flow for the last twelve months.
DYN has negative Operating Income for the last twelve months.
DYN has negative Net Income for the last twelve months.
DYN's long-term assets (165m USD) exceed its long-term liabilties (74m USD).
DYN's ROE (Return on Equity) for the past 12 months is negative and is equal to -137%.
DYN's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -756%.
DYN's short-term assets (129m USD) exceed its short-term liabilties (51m USD).
DYN has negative three-year average ROE (Return on Equity): -63%. The company is not efficient at transforming stockholders' equity into net income.
DYN has negative three-year average ROIC (Return on Invested Capital): -517%. The company is not efficient at using invested capital to generate operating income.
DYN's D/E (Debt to Equity) is very low and is equal to 0.
DYN's Altman Z-Score is very low and is equal to -1.67.
Fundamental Analysis
Dyne Therapeutics Inc
Balance Sheet Decomposition
Dyne Therapeutics Inc
| Current Assets | 129.4m |
| Cash & Short-Term Investments | 123.1m |
| Other Current Assets | 6.3m |
| Non-Current Assets | 35.7m |
| PP&E | 33.4m |
| Other Non-Current Assets | 2.3m |
| Current Liabilities | 51.1m |
| Accounts Payable | 22.9m |
| Accrued Liabilities | 28.2m |
| Non-Current Liabilities | 22.7m |
| Other Non-Current Liabilities | 22.7m |
Earnings Waterfall
Dyne Therapeutics Inc
|
Revenue
|
0
USD
|
|
Operating Expenses
|
-242.2m
USD
|
|
Operating Income
|
-242.2m
USD
|
|
Other Expenses
|
6.2m
USD
|
|
Net Income
|
-235.9m
USD
|
Free Cash Flow Analysis
Dyne Therapeutics Inc
DYN Profitability Score
Profitability Due Diligence
Dyne Therapeutics Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
Score
Dyne Therapeutics Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
DYN Solvency Score
Solvency Due Diligence
Dyne Therapeutics Inc's solvency score is 53/100. The higher the solvency score, the more solvent the company is.
Score
Dyne Therapeutics Inc's solvency score is 53/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
DYN Price Targets Summary
Dyne Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for
DYN
is 38.51 USD
with a low forecast of 20.2 USD and a high forecast of 58.8 USD.
Ownership
DYN Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
DYN Price
Dyne Therapeutics Inc
| Average Annual Return | -20.19% |
| Standard Deviation of Annual Returns | 15.41% |
| Max Drawdown | -85% |
| Market Capitalization | 2B USD |
| Shares Outstanding | 81 958 096 |
| Percentage of Shares Shorted | 11.55% |
Company Profile
Dyne Therapeutics Inc
Country
Industry
Market Cap
Dividend Yield
Description
Dyne Therapeutics, Inc. engages in developing innovative life-transforming therapies for genetically driven muscle diseases. The company is headquartered in Waltham, Massachusetts and currently employs 95 full-time employees. The company went IPO on 2020-09-17. The firm is focused on advancing therapeutics for patients with genetically driven diseases. The company is utilizing its FORCE platform to overcome the limitations of muscle tissue delivery and oligonucleotide therapeutics for muscle diseases. Its FORCE platform therapeutics consist of an oligonucleotide payload that it has designed to target the genetic basis of the disease. With its FORCE platform, it has the flexibility to deploy different types of oligonucleotide payloads with specific mechanisms of action that modify target functions. Using its FORCE platform, the Company is assembling a portfolio of muscle disease therapeutics, including its lead programs in myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD), and facioscapulohumeral dystrophy (FSHD). Its therapeutics consist of three components: a Fab, a clinically validated linker, and an oligonucleotide payload that it attaches to its Fab using the linker.
You don't have any saved screeners yet
